Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Leukemia 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Lymphoma 49Burkitt Lymphoma 39Lymphoma, Large B-Cell, Diffuse 37Lymphoma, Follicular 37Myelodysplastic Syndromes 34Lymphoma, Non-Hodgkin 34Multiple Myeloma 32Leukemia, Myeloid, Acute 31Leukemia, Myeloid, Chronic-Phase 30Leukemia, Myeloid, Accelerated Phase 28Lymphoma, Large-Cell, Immunoblastic 27Leukemia, Lymphocytic, Chronic, B-Cell 27Hodgkin Disease 22Blast Crisis 22Lymphoma, Mantle-Cell 21Lymphoma, B-Cell, Marginal Zone 21Graft vs Host Disease 21Neoplasms, Plasma Cell 20Myeloproliferative Disorders 20Dendritic Cell Sarcoma, Interdigitating 20Recurrence 19Leukemia, Myelomonocytic, Chronic 17Leukemia, Biphenotypic, Acute 17Congenital Abnormalities 17Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 15Anemia, Refractory, with Excess of Blasts 15Primary Myelofibrosis 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11pirtobrutinib 11Gemcitabine 11Carboplatin 11glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Methylprednisolone × Clear all
NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Ipsen

Phase 1/2 Completed
400 enrolled 22 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡